Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Multiple Myeloma 427Neoplasms, Plasma Cell 68Lymphoma, Mantle-Cell 66Lymphoma 65Recurrence 64Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Carcinoma, Non-Small-Cell Lung 24Immunoglobulin Light-chain Amyloidosis 23Leukemia 21Hodgkin Disease 17Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Hematologic Neoplasms 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Cisplatin 8Carboplatin 8Bevacizumab 8Pleurodesis 7Talc 6Paclitaxel 6Docetaxel 5Povidone-Iodine 4Doxycycline 4Taxes 3Gemcitabine 3Drug Therapy 3Chest Tubes 3aldesleukin 2Zoledronic Acid 2Trastuzumab 2Thoracoscopy 2Sodium Chloride 2Silver Nitrate 2Pharmaceutical Preparations 2Nivolumab 2Interleukin-2 2Fluorodeoxyglucose F18 2Fentanyl 2Erlotinib Hydrochloride 2Cetuximab 2Bortezomib 2viscum album peptide 1tocilizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pleural Effusion, Malignant × Bortezomib × Clear all
NCT00118183 2013-06-04

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
62 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00052338 2013-01-23

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡